Clinical Trial Update: Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH) [Phase 2, Phase 3]

View source ↗

Summary

An open-label Phase 2/3 trial evaluating ELA026 for secondary Hemophagocytic Lymphohistiocytosis (sHLH) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• ELA026

Snippet

Sponsor: Electra Therapeutics Inc. | Conditions: Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | Phase 2, Phase 3 | Status: RECRUITING